Abstract
I have read with great interest the recent study by Khorshied et al. [1], which has been published in the Medical Oncology. The authors investigated the possible association between genetic polymorphisms in methylenetetrahydrofolate reductase (MTHFR; EC: 1.5.1.20; OMIM: 607093) at nucleotides 677 (C677T, rs.1801133) and 1298 (A1298C, rs.1801131) and the risk of chronic myeloid leukemia (CML) in an Egyptian sample. The authors included 97 CML patients and 130 ageand gender-matched healthy controls in their study. They found that there is no significant association between these polymorphisms and the susceptibility to CML. I would like to make a few comments about the study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
